Amlodipine Indications
Amlodipine is FDA-approved for three primary indications: hypertension (to lower blood pressure), coronary artery disease including chronic stable angina and vasospastic angina (Prinzmetal's variant angina), and to reduce hospitalization for angina and coronary revascularization procedures in patients with angiographically documented CAD without heart failure or ejection fraction <40%. 1
Primary Indications
1. Hypertension
Amlodipine is indicated for treating hypertension to lower blood pressure, which reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions 1. It can be used as monotherapy or in combination with other antihypertensive agents.
Specific populations where amlodipine is particularly effective:
- Black adults with hypertension: In black patients without heart failure or chronic kidney disease (including those with diabetes), amlodipine is a preferred first-line agent alongside thiazide diuretics, as it is more effective than ACE inhibitors or ARBs for blood pressure reduction and cardiovascular outcomes 2
- Pediatric hypertension: FDA-approved for children 6-17 years at 2.5-5 mg daily 3
- Pregnancy: While labetalol and extended-release nifedipine are preferred first-line agents, amlodipine does not appear to be associated with heightened risk of major congenital malformations, though data are limited 4
2. Coronary Artery Disease
Chronic Stable Angina: Amlodipine is indicated for symptomatic treatment of chronic stable angina, used alone or with other antianginal agents 1. In heart failure patients with angina, amlodipine is recommended when angina persists despite beta-blocker therapy (Class I recommendation) 5.
Vasospastic Angina (Prinzmetal's or Variant Angina): Indicated for confirmed or suspected vasospastic angina as monotherapy or combination therapy 1.
Angiographically Documented CAD: In patients with recently documented CAD by angiography without heart failure or ejection fraction <40%, amlodipine reduces the risk of hospitalization for angina and coronary revascularization procedures 1.
3. Special Cardiac Populations
Unstable Angina/NSTEMI: Amlodipine may be used to control ongoing or recurring ischemia-related symptoms in patients already receiving adequate doses of nitrates and beta-blockers, or in those unable to tolerate these agents 6, 7, 8. However, amlodipine and felodipine are reasonably well tolerated by patients with mild LV dysfunction, though their use in UA/NSTEMI has not been extensively studied 6, 8.
Heart Failure with Angina: Amlodipine should be considered as an alternative to beta-blockers for angina relief in heart failure patients who cannot tolerate beta-blockers (Class IIa recommendation) 5. It can also be added to beta-blocker therapy when angina persists (Class I recommendation) 5.
Important Caveats and Contraindications
Heart Failure with Reduced Ejection Fraction (HFrEF): Routine use of calcium channel blockers including amlodipine is NOT recommended in HFrEF patients (Strong recommendation, moderate-quality evidence) 9. The PRAISE and PRAISE-2 trials showed no mortality benefit with amlodipine in HFrEF 9. However, amlodipine may be considered for persistent hypertension or angina symptoms despite guideline-directed medical therapy 9.
Avoid other calcium channel blockers: Diltiazem, verapamil, nifedipine, and felodipine should be avoided in HFrEF patients 9. Verapamil and diltiazem should also be avoided in patients with pulmonary edema or severe LV dysfunction 6, 7, 8.
Common side effects: Peripheral edema (most common), headache, flushing, dizziness, and palpitations—more common with the 10 mg dose 6, 7, 8, 10, 11.
Pharmacologic Advantages
Amlodipine's unique pharmacokinetic profile makes it particularly suitable for once-daily dosing: long half-life (35-50 hours), low renal clearance, and sustained antihypertensive effect for >24 hours following a single dose 10, 12. Blood pressure control is maintained even when a dose is missed, providing continuous protection in case of incidental noncompliance 10.